Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate designed to specifically deliver the cytotoxic drug DM1 (a derivative of maytansine) to HER2+ breast cancer cells (139–141). This evidence concerns the gene ERBB2 and breast carcinoma.